

Effect of pamidronate on bone loss and implant stability after total hip arthroplasty

Submission date 06/01/2003	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 06/01/2003	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 10/10/2007	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr Jeremy Wilkinson

Contact details
Bone Metabolism Group
University of Sheffield
Division of Clinical Sciences
Northern General Hospital
Herries Road
Sheffield
United Kingdom
S5 7AU
+44 (0)114 271 4705
wilkomark@aol.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Periprosthetic bone loss after total hip replacement

Interventions

Pamidronate sodium as a single 90 mg infusion versus saline infusion given on the 5th day postoperatively after total hip arthroplasty

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Pamidronate

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/2002

Completion date

01/01/2004

Eligibility

Key inclusion criteria

Men and women undergoing primary total hip arthroplasty for osteoarthritis of the hip.

Participant type(s)

Patient

Age group

Not Specified

Sex

Both

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/2002

Date of final enrolment

01/01/2004

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Bone Metabolism Group
Sheffield
United Kingdom
S5 7AU

Sponsor information

Organisation

Arthritis Research Campaign (ARC) (UK)

Sponsor details

Copeman House
St Mary's Court
St Mary's Gate
Chesterfield
Derbyshire
United Kingdom
S41 7TD

-

info@arc.org.uk

Sponsor type

Charity

Website

<http://www.arc.org.uk>

ROR

<https://ror.org/02jkpm469>

Funder(s)

Funder type

Charity

Funder Name

Arthritis Research Campaign (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/01/2005		Yes	No